Kliniken Essen-Mitte

Hospital


Location: Essen, Germany (DE) DE

ISNI: 0000000100064176

ROR: https://ror.org/03v958f45

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Management of systemic lupus erythematosus—Including secondary antiphospholipid syndrome, fertility and pregnancy: S3 guidelines of the German Society for Rheumatology and Clinical Immunology and the German Society for Neurology (DGN), German Society for Internal Medicine (DGIM), German Cardiac Society (DGK), Society for Thrombosis and Hemostasis Research (GTH), German Society for Hematology and Medical Oncology (DGHO), German Society for Pediatric and Adolescent Medicine (DGKJ), Society for Pediatric and Adolescent Rheumatology (GKJR), German Society for Nephrology (DGfN), German Society for Pneumology and Ventilation Medicine (DGP), German Rheumatism League National Association, Lupus Erythematosus Self-help Community, German Dermatological Society (DDG). Version: 1.2 Management des systemischen Lupus erythematodes – inklusive sekundärem Antiphospholipidsyndrom, Kinderwunsch und Schwangerschaft: S3-Leitlinie der Deutschen Gesellschaft für Rheumatologie und Klinische Immunologie e. V. und Deutsche Gesellschaft für Neurologie e. V. (DGN), Deutsche Gesellschaft für Innere Medizin e. V. (DGIM), Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), Gesellschaft für Thrombose und Hämostaseforschung e. V. (GTH), Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e. V. (DGHO), Deutsche Gesellschaft für Kinder- und Jugendmedizin e. V. (DGKJ), Gesellschaft für Kinder- und Jugendrheumatologie e. V. (GKJR), Deutsche Gesellschaft für Nephrologie e. V. (DGfN), Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e. V. (DGP), Deutsche Rheuma-Liga Bundesverband e. V., Lupus Erythematodes Selbsthilfegemeinschaft e. V., Deutsche Dermatologische Gesellschaft e. V. (DDG). Version: 1.2 (2025) Mucke J, Anders HJ, Aringer M, Berlit P, Böltz S, Burchardi FC, Dörner T, et al. Journal article, Review article [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial (2025) Pabst KM, Weber MM, Laschinsky C, Sandach P, Bartel T, Küper AT, Kessler L, et al. Journal article Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial (2025) Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, et al. Journal article CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism (2025) Sinn M, Lohneis A, Mohamed O, Roderburg C, Hellmann M, Südhoff T, Christoph DC, et al. Journal article AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025 (2025) Thill M, Janni W, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, et al. Journal article, Review article AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025 (2025) Park-Simon TW, Müller V, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, et al. Journal article, Review article Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial (2024) Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, et al. Journal article Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease (2024) Ramachandran D, Tyrer JP, Kommoss S, DeFazio A, Riggan MJ, Webb PM, Fasching P, et al. Journal article Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (2024) Schmid P, Cortes J, Dent R, Mcarthur H, Pusztai L, Kümmel S, Denkert C, et al. Journal article Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] (2024) de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, et al. Journal article